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Abstract
Background: Vitamin B12 deficiency is common in older people and the prevalence increases with age. Vitamin
B12 deficiency may present as macrocytic anaemia, subacute combined degeneration of the spinal cord, or as
neuropathy, but is often asymptomatic in older people. The diagnosis and indications for treatment are clear for
individuals with low plasma levels of vitamin B12 in the setting of megaloblastic anaemia and neuropathy, but the
relevance of treatment of vitamin B12 deficiency in the absence of such clinical signs is uncertain.
Methods: The aim of the present study is to assess whether dietary supplementation with crystalline vitamin B12
will improve electrophysiological indices of neurological function in older people who have biochemical evidence
of vitamin B12 insufficiency in the absence of anaemia. To test this hypothesis we designed a randomized double-
blind placebo-controlled trial involving 200 older people aged 75 years or greater who were randomly allocated to
receive either a daily oral tablet containing 1 mg vitamin B12 or a matching placebo tablet. The primary outcome
assessed at 12 months is change in electrophysiological indices of peripheral and central neurosensory responses
required for mobility and sensory function. We here report the detailed study protocol.
Conclusions: In view of the high prevalence of vitamin B12 deficiency in later life, the present trial could have
considerable significance for public health.
Background and rationale
Low vitamin B12 status is common among older people
[1], and is most frequently a result of age-related gastric
atrophy which decreases the production of acid neces-
sary for the release of vitamin B12 from the food matrix,
and a decrease in active intrinsic factor which results in
vitamin B12 malabsorption [2,3]. Crystalline vitamin
B12 is however, relatively well absorbed in most older
people [4], and oral supplementation with high-dose
crystalline vitamin B12 is recommended to ensure
adequate vitamin B12 status in later life [5,6]. Neverthe-
less, vitamin B12 treatment is widely administered by
intramuscular injection in the United Kingdom.
Individuals with vitamin B12 deficiency associated
with macrocytic anaemia may present with peripheral
neuropathy (sensory disturbances in the extremities
such as tingling and numbness, and impaired vibration
and joint position sense) and myelopathy that can pro-
gress, if untreated, to severe motor problems [5]. The
main histopathological finding in vitamin B12 deficiency
is a loss of myelin in the white matter of the spinal cord
(posterior and lateral columns) and of peripheral nerves,
and to a lesser degree in the brain [7]. The mechanism
for loss of myelin is not fully understood; while vitamin
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B12 is required for methylation reactions involved in
homocysteine and folate metabolism, vitamin B12 defi-
ciency does not affect the methylation of myelin basic
protein [8]. Clinical observations on individuals with
pernicious anaemia suggests that intra-muscular treat-
ment with high-dose vitamin B12 over a period of a few
weeks typically resolves the neurological symptoms in
most cases [9,10], suggesting a reversible biochemical
state, and not an irreversible degeneration or loss as
seen in some forms of dementia.
There is considerable uncertainty about the relevance
of vitamin B12 supplementation for neurological func-
tion in older people in the absence of anaemia or
macrocytosis. Indeed, there is currently no evidence
from randomised controlled trials assessing the effects
of dietary supplementation with vitamin B12 on periph-
eral and central nerve conduction and neurosensory
processing. The lack of trial evidence is surprising given
that electrophysiological abnormalities associated with
vitamin B12 deficiency have been repeatedly demon-
strated [11,12]. A single blind before and after study
demonstrated improvements, following vitamin B12
treatment, in quantitative electroencephalography in 16
patients [13]. The use of quantitative electroencephalo-
graphy demonstrates the presence of altered neural
function in the absence of clinical symptoms of vitamin
B12 deficiency, supporting the concept of using electro-
physiological tools to quantify vitamin B12 status.
This is the first randomised controlled trial designed
to determine whether supplementation of cognitively
normal older people who have low vitamin B12 status in
the absence of anaemia will benefit electrophysiological
indices of peripheral and central neurosensory
responses. Demonstrating that vitamin B12 dependent
neurological impairment is present and reversible even
in individuals without clinical symptoms could have
considerable implications for public health.
Design and methodology
The study is designed as a double-blind randomised pla-
cebo-controlled trial. The procedures are illustrated
schematically in Figure 1, and detailed in the text. The
aim of this trial is to assess whether dietary supplemen-
tation with crystalline vitamin B12 will benefit electro-
physiological indices of neurological function and
cognitive function in older people with biochemical evi-
dence of vitamin B12 deficiency in the absence of
anaemia.
Approximately 10 National Health Service general
practices, members of the Medical Research Council
General Practice Research Framework (GPRF) or the
Primary Care Research Network will be recruited. The
practices will be situated in the South East of England
to facilitate attendance at King’s College Hospital.
Community-dwelling individuals aged over 75 years of
age will be identified from practice registers of partici-
pating general practices. The medical records of identi-
fied potential participants will be searched and those
with pre-existing medically diagnosed diabetes and
dementia will be excluded. Individuals with either Type
1 or Type II diabetes will be excluded because of their
increased susceptibility for neuropathy that is unrelated
to vitamin B12 deficiency. Individuals with pernicious
anaemia will be excluded where vitamin B12 treatment
is indicated. Individuals known to have alcohol addiction
will be excluded, as will individuals with a history of epi-
lepsy or who have implanted metallic devices such as
pacemakers (for whom neurophysiological testing is
contraindicated). In addition the list of potential partici-
pants will be checked by the named General Practitioner
in the clinic who will use discretion to exclude indivi-
duals considered unsuitable to participate in the study
(e.g. recent bereavement, terminal illness).
Potentially eligible individuals identified by this pro-
cess will each receive a letter and information sheet
from their general practice outlining the nature and
relevance of the study. The invitation letter will also act
as a screen for potential participants who are currently
consuming vitamin B12 supplements (either singly or in
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Figure 1 Flow chart of OPEN study protocol.
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combination with other vitamins and minerals) or have
received a vitamin B12 injection in the last 6 months.
Participants reporting the current daily use of vitamin
B12 supplements or a vitamin B12 injection within the
previous 6 months will be excluded from the trial.
Potential participants will be invited to make an
appointment with the research nurse at their local gen-
eral practice. The invitation letter will explicitly state
that if they do not wish to participate in the study it will
not alter their health care in any way. Non-responders
will be sent one reminder three weeks after the initial
mailing.
On attending at their general practice, potential partici-
pants will be fully informed by the research nurse about
the nature and relevance of the study and what will be
involved if they agree to take part. The nurse will check
with the patient that they do not have a pacemaker, are
not epileptic, are not currently taking vitamin B12 sup-
plements on a daily basis and have not had a vitamin B12
injection within the previous 6 months. Potentially eligi-
ble participants will be asked if they have been diagnosed
with diabetes (confirmed by medical record check), and
asked to have an assessment of cognitive function using
the Mini Mental State Examination (MMSE) [14]. Partici-
pants with an MMSE score of less than 24 (out of a maxi-
mum of 30) will be excluded. The cut-off of less than 24
has traditionally been used as a marker for possible
dementia in adults. Those with an MMSE score of less
than 24 will not be included further, will be thanked for
their time and co-operation and will be asked if they wish
to make an appointment with their General Practitioner
to discuss their MMSE result.
Potential participants without a diagnosis of diabetes
and with an MMSE score of 24 or greater will be asked
to give full informed consent and to provide a blood
sample and, if eligible, have their results and contact
information passed to the OPEN study team. Partici-
pants providing informed consent will be asked to pro-
vide a 4.5 ml blood sample to assess serum vitamin B12
and haemoglobin concentrations.
Research nurses in the participating general practices
will provide the results of the blood tests to all potential
participants. Eligible individuals are defined as those
with a low but not deficient vitamin B12 status who are
not anaemic (serum vitamin B12 levels ≥ 107 pmol/l
and <210 pmol/l - Beckman Coulter assay [15] and hae-
moglobin levels ≥ 11 g/l for women and ≥ 12 g/l for
men). Individuals found to have above average serum
vitamin B12 status (≥ 210 pmol/l - Beckman Coulter
assay) will be excluded from the study. Individuals
found to have very low vitamin B12 levels (< 107 pmol/l
- Beckman Coulter assay) or/and found to be anaemic
(haemoglobin concentration <11 g/l for women and
<12 g/l for men) will be referred to their General
Practitioner for normal practice treatment and excluded
from the study.
The contact details of eligible individuals will be
passed to the OPEN study manager, who will make tele-
phone contact with participants to restate the nature
and relevance of the study and what will be involved if
they agree to take part and to invite them to attend a
baseline appointment at King’s College Hospital. In
addition, participants will be asked to complete a ques-
tionnaire on diet and psychological health at home and
bring it with them to their baseline appointment. Trans-
portation will be provided locally for the participant
from their home to the hospital.
At the baseline visit, potential participants will be
given the opportunity to discuss the study and ask any
questions before being invited to give full informed con-
sent to participate in the study. Individuals giving
informed consent will be enrolled in the trial and shown
how to contact the OPEN study manager and obtain
more information from the study web-site [16].
The OPEN study manger will telephone the central
randomisation service to randomise the participant, giv-
ing identifying details and the participant’s age. Rando-
misation will allow secure blind allocation of eligible
participants to one or other arm of the study. Following
random allocation a trial number will be given to each
study participant. This will also be used to identify the
supply of dietary supplements to be prescribed for each
participant (see Dietary Intervention below). The study
number will be entered on the participant’s entry form.
Pre-labelled identical-looking packs of dietary supple-
ments will be stored at King’s College Hospital. Minimi-
sation criteria will be used to ensure a balance of key
prognostic factors using the following two criteria: age
group (75-79 and 80+ years) and gender. These two cri-
teria have been selected as there are clear age and gen-
der gradients in vitamin B12 status.
Participants will be asked to complete a questionnaire
including a sequence of cognitive function tests, provide
a blood sample, and undertake a series of neurophysio-
logical function tests (see Baseline Data Collection
below) which will in total take approximately 75 min-
utes to complete. Any couples recruited to the study
will undertake their assessments separately.
The OPEN study has received ethics committee
approvals from the National Research Ethics Service
(08/H0305/18) and the London School of Hygiene &
Tropical Medicine ethics committee (no. 5298). The
OPEN study is registered on ISRCTN (54195799).
Outcome measures
Primary outcome
The primary outcome as assessed 12 months after ran-
domisation will be amplitude of tibial motor evoked
Dangour et al. Nutrition Journal 2011, 10:22
http://www.nutritionj.com/content/10/1/22
Page 3 of 8
response. The negative peak amplitude of the peripher-
ally evoked compound muscle action potential reflects
the number of motor axons that can be accessed by an
electrical stimulus which in turn reflects muscle strength
and is therefore a clinically useful parameter in the
assessment of treatments which might affect the number
or efficacy of motor axons. Lower limb nerves are more
affected than upper limb nerves by length dependent
axonal dysfunction which is likely to be the case in vita-
min B12 deficiency. Compound muscle action potentials
(CMAPs) recorded over the abductor hallucis muscle
evoked by supramaximal posterior tibial nerve stimuli at
the ankle therefore form the primary outcome measure
[12,17].
Secondary outcomes
- Cognitive performance, including tests of memory,
executive function and psychomotor speed.
- Functional performance as measured by the timed
up and go test.
- Knee and ankle jerk, joint position and vibration
sense as clinical markers of neurological function.
- Psychological health as measured by the General
Health Questionnaire.
- Peripheral sensory nerve function as measured by
superficial peroneal, sural, median and ulnar sensory
action potential amplitudes and conduction
velocities.
- Peripheral motor nerve function as measured by
common peroneal, median and ulnar compound
muscle action potential amplitudes; common pero-
neal, tibial, median and ulnar and tibial conduction
velocities; and common peroneal, tibial, median and
ulnar minimum F-wave latencies.
- Central motor conduction as measured by cortico-
motor threshold, motor evoked potential amplitude,
central motor conduction time, and cortical silent
period duration in abductor hallucis and abductor
digiti minimi muscles.
- Haematological markers.
- Number of hospitalisations for cardiovascular
events (myocardial infarction [MI] and stroke) in
the12 months after randomisation.
- Death.
Sample size and recruitment
A sample size of 200 individuals in total (100 per arm)
is proposed. With 30% drop-out over 12 months, this
would give 90% power to detect at least a 28% change
in tibial motor amplitude with 5% significance. Tibial
CMAP amplitude is a marker for foot muscle strength
and a 28% increase would be associated with clinically
relevant improvements in physical coordination and
balance. The extent of correlation between measures of
tibial motor amplitude between baseline and follow up
in the placebo group is currently not known, but if it is
high a smaller effect size will be detectable. For example,
with an average test-retest correlation across the study
of 0.6 and a sample size of 200 individuals, we will be
able to detect a 21% change in tibial motor amplitude.
In order to attain this sample size it is expected that
approximately 4000 individuals, pre-screened for dia-
betes, dementia and alcoholism, will be selected from
the registers of 10 participating general practices.
Experience from a previous study among older people
in England and Wales [18] suggests that of the potential
participants, 800 (or 1/5 of total invited) will agree to
attend a screening appointment. It is estimated that it
will take 15 months to recruit participants for the trial.
Data from the Banbury B12 Study has been used to
define average and low vitamin B12 status [15]. Indivi-
duals with serum vitamin B12 concentrations <210
pmol/l (the Banbury B12 study average), and ≥ 107
pmol/l the cut-off for serum vitamin B12 deficiency
(Beckman Coulter assay) with no anaemia will be
included in the study. We expect that of the 800 attend-
ing the screening appointment, approximately 270 indi-
viduals will meet the entry criteria for the study.
Baseline (pre-intervention) data collection
• At home prior to appointment
- Basic data related to diet and alcohol consumption.
- Psychological health assessed using the 30-item
General Health Questionnaire (GHQ-30) [19].
• To enable randomization
- Date of birth
- Gender
- Confirmation that no pacemaker or other metallic
device is fitted
- Consent
• At baseline visit
- Basic socio-demographic data on age, gender, car-
diovascular health (5-year history of hospitalisation
for MI or stroke) and educational achievement.
- Cognitive function: simple paper and pencil tests
to assess memory and executive function, as well as
simple and choice reaction time as markers of psy-
chomotor speed.
- Timed up and go [20] assesses the time taken for a
participant to rise from an arm chair, walk 3 metres,
turn around and return to sit on the chair and is a
good marker of mobility among older people. This
may prove an important marker of position sense
and gait that are affected in vitamin B12 deficiency.
- Clinical markers of neurological function: pre-
sence/absence of knee and ankle jerks, joint position
sense and vibration sense in the left and right leg.
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- Basic anthropometric measures: height and weight
will be measured using standardised procedures in
order to enable the calculation of the Body Mass
Index (a basic marker of body size) which may be
used as a co-variate in analysis.
- Current prescription medication (information pro-
vided by General Practice).
- Blood samples to determine baseline status of vita-
min B12, holotranscobalamin, total homocysteine
and folate, and basic haematological parameters. A
sample of blood will be collected into 2 × 5 ml
serum separating tubes for subsequent measurement
of total homocysteine (tHcy) and holotranscobalamin
(holoTC), folate and vitamin B12. This blood sample
will be allowed to clot and centrifuge at 2600 rpm
for 10 min at a temperature of 4 degrees Centigrade
within 2 hours of collection. This sample will be
stored at -80 degrees Centigrade prior to laboratory
analyses. Serum vitamin B12 will be measured by
microbiological assay using L.Leichmanii as the
growth organism; tHcy concentrations will be deter-
mined by an Abbott IMx analyzer, and serum
holoTC will be measured using the AXIS-Shield
radiommunoassay method [21]. A second blood
sample will be collected into a 4 ml Vacutainer tube
containing EDTA for haematological parameters
(haemoglobin, hematocrit, mean corpuscular
volume). Blood samples will be couriered on dry ice
in batches from LSHTM to Department of Biochem-
istry, Trinity College, Dublin, Ireland for analysis of
vitamin B12, holoTC, folate and tHcy. Haematologi-
cal parameters will be assessed using a central
laboratory. A sample of DNA will be isolated for
each participant and stored for 10 years for future
research into potential genetic influences on neuro-
cognitive health in older people.
Obtaining informed consent, randomisation and the
collection of baseline information by the OPEN study
manager will take approximately 45 minutes. The parti-
cipant will then undergo neurophysiological testing.
Nerve conduction velocity and amplitude
Peripheral nerve conduction
Nerve conduction studies of the right superficial pero-
neal, sural, common peroneal, tibial, median and ulnar
nerves will be performed using standard techniques. All
techniques will use surface electrodes and limb tempera-
ture will be controlled to be above 28 degrees Centi-
grade by suitable heating and blankets. Superficial
peroneal, sural, median and ulnar sensory action poten-
tial amplitude and conduction velocity will be measured.
Common peroneal, tibial, median and ulnar motor con-
duction will be measured by recording from extensor
digitorum brevis, abductor hallucis, abductor pollicis
brevis and abductor digiti minimi respectively. Nerves
will be stimulated supramaximally at proximal and distal
sites and conduction velocity in the forearm and distal
leg nerve segments calculated. Compound muscle action
muscle potential (CMAP) amplitude, distal motor
latency and F-wave latency (a measure of conduction
times from the distal stimulation site to the spinal cord)
will also be measured.
Central motor conduction
Central motor conduction in the corticospinal tract will
be measured by transcranial magnetic stimulation which
non-invasively and painlessly excites motor cortex [22].
The time to response in a given muscle is subtracted
from an estimate of the peripheral nerve conduction to
calculate the central motor conduction time (CMCT).
Additionally, from the corticomotor threshold an esti-
mate of cortical inhibitory systems, the cortical silent
period, will be obtained.
A magnetic stimulator providing a monophasic pulse
and driving a 13 cm diameter circular coil placed over
the vertex to excite the hand area of motor cortex will
be used. The threshold for excitation will be determined
using a standard technique [23]. With the abductor
digiti minimi muscle partially activated voluntarily, 8 sti-
muli at 1.2 times threshold will be delivered to evoke
motor evoked potentials (MEPs), the mean amplitude
and minimal latency of which will be measured. By
using the F-wave latency CMCT will be calculated. Cor-
tical silent period, a measure of inhibitory circuits
excited by the stimulus will also be measured. Similarly,
using a double cone coil, the leg area of motor cortex
will be excited and the MEPs evoked in abductor hallu-
cis also measured. Each participant will receive a maxi-
mum of 70 brain stimuli.
The collection of neurophysiological data will take
approximately 30 minutes. Participants will need to
expose the distal parts of upper and lower limbs. Supra-
maximal nerve stimuli are routinely used daily to inves-
tigate neurological conditions with minimal discomfort.
Magnetic brain stimulation causes a minimal sensation
like a light tap on the scalp. Participants who are found
to have significant neurological deficit will be treated in
accordance with standard clinical practice guidelines.
Dietary Intervention
Following the completion of baseline testing, participants
will be introduced to the dietary intervention which will
take the form of a daily tablet, identical in size, shape, col-
our, smell and taste for both the intervention and placebo
arms of the trial. The intervention tablets will each contain
1 mg vitamin B12. We have selected this level of daily vita-
min B12 supplementation, which is above the established
Dangour et al. Nutrition Journal 2011, 10:22
http://www.nutritionj.com/content/10/1/22
Page 5 of 8
recommended intake, as it has been proven effective in
resolving indices of vitamin B12 deficiency in older people
[24]. This dose is likely to be necessary to evaluate the effect
of subclinical deficit in older people who may have limited
absorption of dietary vitamin B12 due to chronic gastritis
or defective ileal absorption. Only 1-2% of an oral dose of
vitamin B12 is absorbed (by passive diffusion), providing an
absorbed amount of 10-20 μg/day [25]. It is also possible
that a lower dose may be effective, but the current pro-
posed dose is safe [5] (there is no defined upper limit for
vitamin B12), and likely to optimize any potential efficacy.
The OPEN study manager will explain the importance
of consuming the supplement every day preferably with a
meal, suggesting that it should become part of their daily
routine, for example by always consuming the supplement
at breakfast time. Participants will be given a 4 month sup-
ply of supplements at the baseline hospital visit and will be
sent further supplies by post at 4 and 8 months.
Final participant assessment
After 12 months of intervention, the OPEN study man-
ager will arrange transportation for the participant from
their home to King’s College Hospital. All participants
will be assessed for:
- psychological health: as at baseline;
- cognitive health: as at baseline;
- timed up and go: as at baseline;
- clinical markers of neurological function: as at
baseline;
- anthropometry: as at baseline;
- cardiovascular health: record of hospital admissions
for MI or stroke between baseline and 12 month
appointment;
- haematological indices: as at baseline;
- nerve conduction: as at baseline.
Trial monitoring
The primary objective of trial monitoring is to ensure
that participants adhere to the study regimen, and sec-
ondly to minimize drop-out from the study by ensuring
frequent contact between participants and the OPEN
study manager. Participants will be telephoned by the
OPEN study manager soon after the baseline hospital
visit to answer any queries and ensure compliance with
the trial regimen, and every 2 months throughout the
study (6 telephone calls in total). During these calls, par-
ticipants will be reminded of the importance of the study
and of the need to comply with the study protocol.
The OPEN study manager will also record any infor-
mation a participant volunteers regarding any discom-
fort caused by the supplement. The recognised side-
effects of oral vitamin B12 supplementation include
mild transient diarrhoea, and itching. These discomforts
are rare at this dosage, generally mild and decrease over
time, and the OPEN study manager will provide reassur-
ance to any concerned participants. The 2 month tele-
phone calls will also allow the OPEN study manager to
maintain contact with the trial participants. This will
allow changes in personal information or ill health and
death to be accurately recorded. At the 4 and 8 month
telephone calls, the OPEN study manager will arrange
for a delivery of a further supply of supplements to the
participants home.
Serious Adverse Events
Participating practices will be asked to report any possi-
ble serious adverse events to the OPEN study manager.
Any serious adverse events reported by participants to
the study manager during 2-monthly follow-up calls will
be verified with the General Practice.
Longer term follow-up
Further follow-up may be the subject of a separate pro-
tocol. So that the study organisers do not lose contact
with patients should they move address and also to fol-
low up on vital status, including death, participants are
being asked to give their agreement for their names and
National Health Service (NHS) numbers to be sent to
the NHS Central Register.
Data analyses
Primary analysis will be carried out based upon the
groups as randomised ("intention to treat”). Results will
be presented as appropriate effects sizes with a measure
of precision (95% confidence intervals). Covariates such
as gender and baseline age, and vitamin B12, folate and
homocysteine status will be adjusted for in the analysis.
Further exploratory analysis will be based on those
patients who fully follow the treatment protocol.
Trial organisation
Investigators
1. Alan Dangour (Principal Investigator PI): public
health nutritionist based at the London School of
Hygiene & Tropical Medicine (LSHTM), will co-
ordinate and manage the overall running of the trial.
2. Elizabeth Allen: medical statistician based at
LSHTM.
3. Diana Elbourne: senior trialist based at LSHTM,
will co-ordinate activity at the LSHTM Data Coordi-
nating Centre.
4. Astrid Fletcher: senior epidemiologist based at
LSHTM.
5. Ricardo Uauy: senior public health nutritionist
based at LSHTM.
6. Kerry Mills: Professor of Clinical Neurophysiology
responsible for the collection and interpretation of
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all electrophysiological data based at King’s College
Hospital.
7. Louise Letley: senior nurse manager for the MRC
GPRF with extensive experience of coordinating
nurse managed research projects in primary care.
Has overall responsibility for the research nurses
involved in the study based in General Practices and
for the management of quality control within the
practices.
8. Robert Clarke: senior clinical epidemiologist based
at University of Oxford.
9. Marcus Richards: senior neuropsychologist based
at the MRC Centre for Lifelong Health and Ageing,
London.
Project Management Group
A Project Management Group (comprising principal
investigators, trial manager, senior research nurse, data-
base manager and statistician) will run the trial on a day
to day basis to ensure the smooth operation of the pro-
ject. Regular review meetings will be held with other
members of the team as appropriate.
Trial Steering Committee
The overall scientific aspects of the project will be man-
aged by a Steering Committee. The Trial Steering Com-
mittee comprises expert independent advisors Dr.
Edward Reynolds, Consultant Neurologist and Honorary
Senior Lecturer, King’s College School of Medicine
(Chair), Dr. Michael Donaghy, Consultant Neurologist
and Reader in Clinical Neurology, University of Oxford,
Dr. Amrit Takhar, General Practitioner, Wansford Sur-
gery, Peterborough and lay members Mrs. Ursula Shine
and Mrs. Yvonne Davidson [stood down in April 2009].
Data Monitoring and Safety Committee
An independent Data Monitoring and Safety Committee
(DMSC) has been established. The membership com-
prises Prof. Richard Hughes, Emeritus Professor or Neu-
rology, King’s College London (Chair), Prof. Lisette de
Groot, Professor of Human Nutrition, Wageningen Uni-
versity and Prof. Graham Dunn, Professor of Medical
Statistics, Manchester University. The role of the DMSC
is to check on safety by treatment allocation. Although
vitamin B12 is not expected to lead to adverse conse-
quences, it is important to monitor safety. In addition,
the DMSC will assess compliance data by random treat-
ment allocation and consider data at trial entry by ran-
dom allocation in order to be able to interpret the
compliance and adverse events data. The committee will
meet at the start of the trial to agree terms of reference
and then at the end of the recruitment period and every
6 months or as agreed.
Medical Research Council General Practice Research
Framework (GPRF)
The responsibilities of the GPRF are to select and sup-
port general practices from which the participants are to
be drawn. The GPRF will train, monitor and support
research nurses throughout the trial, assure recruitment
and compliance to the trial protocol.
Data Co-ordinating Centre
The Data Co-ordinating Centre (DCC) will be based at
the LSHTM. The responsibilities of the DCC are to set-
up and run systems for data entry, data verification, and
to conduct interim and final analyses.
King’s College Hospital
The responsibilities of the investigator at King’s College
Hospital are to carry out the collection of neurophysio-
logical data at baseline and after 12 months as specified
in the protocol, and coordinate with the study manager
to ensure that participants appointments are made at a
mutually convenient time, interpret primary data and
forward cleaned data to the data co-ordinating centre.
Publication Policy
To safeguard the scientific rigour of the trial, data from
this trial will not be presented in public or submitted
for publication without permission of the Trial Steering
Committee. The requirements for authorship will follow
recommended practice in journal guidelines.
Confidentiality
Data handling will be in accordance with the Data Pro-
tection Act. All the research team, including practice
staff, will be made aware of the need for complete confi-
dentiality when dealing with patient information. The
investigators and local coordinators will ensure conser-
vation of records in areas to which access is restricted.
Sponsor
The London School of Hygiene & Tropical Medicine
will act as the main sponsor for the OPEN study. Dele-
gated responsibilities will be assigned locally.
Conclusion
Vitamin B12 deficiency is common in older people, and
although there are several clinical signs of vitamin B12
deficiency, it can often be asymptomatic. Despite signifi-
cant interest and scientific rationale in the role of vita-
min B12 in nerve conduction, there has to date been no
clinical trial investigating the effect of oral vitamin B12
supplementation on electrophysiological indices of neu-
rological function in later life. The current trial is
designed to test the hypothesis that daily dietary supple-
mentation with crystalline vitamin B12 will benefit
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electrophysiological indices of peripheral and central
neurosensory responses required for mobility and sen-
sory function. Demonstrating that vitamin B12 depen-
dent neurological impairment is present and reversible
even in individuals without clinical symptoms could
have considerable public health significance.
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